Spectrum Pharmaceuticals Securities Class Action: New Lead Plaintiff Process Re-Opened for Investors

Investors on Alert: Spectrum Pharmaceuticals Lawsuit Re-opens

On September 18, 2025, a New York federal court reopened the lead plaintiff process in the ongoing securities class action against Spectrum Pharmaceuticals (ticker: SPPI). This important development arrives on the heels of the disqualification of the previously appointed lead plaintiff on August 4, 2025, allowing new investors a chance to join the case. The new deadline for potential investors to apply to be the lead plaintiff is September 24, 2025.

Background of the Lawsuit

This federal class action lawsuit, titled Christiansen v. Spectrum Pharmaceuticals, Inc., et al., has been ongoing in the Southern District of New York since late 2022. The core of the allegations asserts that Spectrum provided false assurances to investors regarding the efficacy of its cancer drug, poziotinib, despite aware of its failures. The lawsuit highlights that, upon disclosure of the U.S. Food and Drug Administration's (FDA) serious concerns over clinical trial outcomes, Spectrum's stock plummeted by more than 37%.

Class Period and Important Dates

Investors who purchased SPPI shares during the class period, which spans from March 17, 2022, to September 22, 2022, are encouraged to act promptly. They also include individuals who received shares of Assertio Holdings (ASRT) after the latter's acquisition of Spectrum, which was finalized on July 31, 2023. This acquisition means that any investor who received ASRT as part of the merger, following their investment in Spectrum during the class period, now may be eligible to represent the class.

The Significance of Acting Now

Hagens Berman, the national law firm handling the case, has stressed the importance of stepping forward for those who suffered significant financial losses. As a lead plaintiff, individuals have a unique opportunity to influence the direction of the lawsuit, ensuring that the voices of all affected investors are represented.

Assertio's Acquisition of Spectrum Pharmaceuticals

It is crucial to understand the context of the acquisition between Assertio Holdings and Spectrum Pharmaceuticals. After the class period, Assertio merged with Spectrum, resulting in shareholders of Spectrum receiving Assertio shares in exchange for their investments. This merger adds another layer of complexity to the securities fraud allegations, providing even more avenues for investors to claim participation in the class action.

Steps for Interested Investors

Hagens Berman is prompting all eligible investors to reach out for further information and possibly become the new lead plaintiff. If you believe you qualify under the aforementioned criteria, now is the time to take action. Potential plaintiffs can visit classactionlaw.com for more details on how to file.

Conclusion: Importance of Corporate Accountability

This case stands as a reminder of the vital role that corporate accountability plays within the pharmaceutical industry, especially when it comes to providing truthful information to investors. The ongoing litigation represents not only a fight for individual financial recovery but also the larger struggle for transparency and integrity in business dealings. Stakeholders with non-public information regarding Spectrum are also encouraged to consider the SEC Whistleblower program, which promises rewards for substantial contributions.

As this case progresses, it is essential for the investor community to stay informed and engaged in the pursuit of justice against corporate misconduct. Investors are urged to act swiftly as the rapidly approaching deadline of September 24, 2025, draws near.